|
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
- Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
-- Cytokinetics, Incorporated (NasdaqGM:CYTK - News) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of...
|
|
|
Gene Activity Variations Predict Lymphoma Survival
Patterns of gene activity in a type of non-Hodgkin lymphoma has given researchers a better understanding of factors that contribute to the survival of patients treated for the disease.Gene activity, or expression, is a measure of...
|
|
|
[external] FDA speeds up review of Cell Therapeutics drug
Puget Sound Business Journal (Seattle) Related News The Food and Drug Administration will expedite its review of whether the cancer drug Zevalin can be used in wider applications.Zevalin is being developed by RIT Oncology LLC, a joint...
|
|
|
FDA speeds up review of Cell Therapeutics drug
Puget Sound Business Journal (Seattle) Related News The Food and Drug Administration will expedite its review of whether the cancer drug Zevalin can be used in wider applications.Zevalin is being developed by RIT Oncology LLC, a joint...
|
|
|
US FDA grants priority review status for Cell Therapeutics' Zevalin
Cell Therapeutics, Inc (CTI) announced that the US Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of...
|
|
|
IRVINE--- Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed On
Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI) and Cell Therapeutics, Inc. (NASDAQ:CTIC)(MTA: CTIC) announced today they have entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, to commercialize and...
|
|
|
Cell Therapeutics gets fast-track evaluation of drug
1--Cell Therapeutics said Monday that its request to expand approved uses for cancer drug Zevalin will get a fast-track review from federal regulators.The U.S. Food and Drug Administration granted priority review to Zevalin, which...
|
|
|
FDA Grants Priority Review on Ibritumomab Tiuxetan Application
FDA Grants Priority Review on Ibritumomab Tiuxetan Application SEATTLE, Dec.1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has...
|
|
|
Stromal Gene Signatures in Large-B-Cell Lymphomas
_ Stromal Gene Signatures in Large-B-Cell Lymphomas.
|
|
|
The International Myeloma Foundation Says Patient Experience -- Longer Survival and Improved Quality of Life -
The International Myeloma Foundation (IMF)'supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians'today said five long-term survivors will match real-life stories to the...
|
|
|
Astex presents updates on AT7519 and AT9283 at the American Society of Hematology (ASH) Conference
Cambridge, England, 1st December, 2008 - Astex Therapeutics Limited, the leading fragment based drug discovery company, today announced that it is to present key findings on two of its clinical stage compounds, AT7519 and AT9283, at the 50th...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
www.allos.com/ - Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
WESTMINSTER, Colo.--(BUSINESS WIRE)-- Allos Therapeutics, Inc.(Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
rapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with Follicular Lymphoma
(BUSINESS WIRE) -- Allos Therapeutics, Inc.(ALTH: ALTH News, chart, profile, more Last: Delayed quote data Add to portfolio Analyst Create alert Insider Discuss Financials Sponsored by: , , ) , a biopharmaceutical company focused on the...
|
|
|
U.S FDA Grants Pralatrexate Orphan Drug Designation for the Treatment of Patients with
Allos Therapeutics, Inc.(Nasdaq:ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that an abstract summarizing interim clinical trial data evaluating SB-743921 is scheduled to be presented as a poster presentation at the 2008 American Society of Hematology (ASH)...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
(MARKET WIRE via COMTEX) -- GSK | Quote | Chart | News | PowerRating -- Cytokinetics, Incorporated (NASDAQ: CYTK | Quote | Chart | News | PowerRating) announced today that an abstract summarizing interim clinical trial data evaluating SB...
|
|
|
Cytokinetics, Inc.: Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008
- Cytokinetics, Incorporated (NASDAQ Poster Presentation at ASH The following abstract is scheduled to be presented at ASH as follows: Abstract #1563: 'A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Administered...
|
|
|
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at the 2008 American Society of
- Cytokinetics, Incorporated (NASDAQ Poster Presentation at ASH The following abstract is scheduled to be presented at ASH as follows: Abstract #1563: 'A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Administered...
|
|
|
ALTH: FDA Grants Orphan Drug Designation for Pralatrexate
Ridgeland, MS, DEC 01, 2008 (EventX/Knobias.com via COMTEX) -- ALTH | Quote | Chart | News | PowerRating -- By Fain Hughes, fhughes@knobias.com Allos Therapeutics, Inc.(ALTH) announced that the FDA granted orphan drug designation to the...
|
